… In addition to CDR1as (Figure S1T), we analyzed LINC00632 isoform expression for a
subset of samples. Interestingly, we observed a switch of LINC00632 isoform expression in …

MDM4 is a promising target for cancer therapy, as it is undetectable in most normal adult
tissues but often upregulated in cancer cells to dampen p53 tumor-suppressor function. The …

Fast, high-throughput methods for measuring the level and duration of protective immune
responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here …

… To determine whether the observed changes were statistically significant based on the two
biological replicates, we applied a moderated t test through the limma algorithm (24, 25), as …

High spliceosome activity is a dependency for cancer cells, making them more vulnerable to
perturbation of the splicing machinery compared to normal cells. To identify splicing factors …

Our study provides a new proof-of-principle for posttranslational regulation of splicing factors
independently of mutations in aggressive T-cell leukemia. It further suggests a new drug …

The extent of and the oncogenic role played by alternative splicing (AS) in cancer are well
documented. Nonetheless, only few studies have attempted to dissect individual gene …

… in the epigenome and therefore persistent change in T cell behavior 16 . In this study, … T
cell cytotoxicity when added during ex vivo T cell expansion, using a model for transient TCR-T …

… for full antigen receptor-mediated T-cell activation and for proper interferon-γ production,
even though loss of PKCα was shown to have no apparent effects on T-cell development and …

… of the transfected T lymphocytes. Moreover, we show that SSOs targeting T cell-specific …
reduction of the protein and consequent modification of T cell function. This technical work paves …